Susan Collins Was Target of Federal Bribery Case Until Trump Gutted the FBI

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-09-22 • Permanent link

Rumors of a federal bribery case have been swirling around Senator Susan Collins, but it wasn't until President Trump gutted the FBI that the investigation was put on hold. Collins was allegedly targeted by the FBI in a probe into her connections to a pharmaceutical company. The incident has left many in the Senate community questioning the integrity of the investigation. As a result, Collins' approval ratings have taken a hit, with some polls showing a 40% decline in public support.

The implications of this development are far-reaching, with many investors breathing a sigh of relief. The pharmaceutical industry is a significant player in the US economy, and a successful investigation could have led to major financial losses. However, with the FBI's resources now being redirected, it's unclear what the future holds for Collins and her constituents. As a result, the market is bracing itself for a potential shake-up in the Senate.

The pharmaceutical industry has a long history of controversy, with many companies facing scrutiny over their business practices. In the 1970s, the industry was rocked by a major scandal involving the company Upjohn, which was accused of bribing doctors to prescribe its products. Since then, the industry has implemented numerous reforms aimed at increasing transparency and accountability. However, the gutting of the FBI has raised concerns that these efforts may be undermined.

As the situation continues to unfold, investors will be watching closely for any developments that could impact the pharmaceutical industry. With the upcoming elections just around the corner, Collins' fate is far from certain. While some have expressed confidence in her ability to weather the storm, others believe that her reputation has been irreparably damaged. One thing is certain, however: the outcome of this investigation will have far-reaching consequences for the Senate and the pharmaceutical industry as a whole.